- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07945145
A Pharmacokinetics Study of GZR33 Injection at Different Injection Sites
A Randomized, Open-Label, Three-Period Crossover Clinical Study to Evaluate the Pharmacokinetics and Safety of GZR33 Injection Administered at Different Injection Sites in Healthy Participants
This trial is conducted in China. This study will be conducted to evaluate the pharmacokinetics and safety of GZR33 Injection administered at different injection sites in healthy participants.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Kunlin Li
- Telefonnummer: 010-80595000
- E-post: Kunlin.li@ganlee.com
Studieorter
-
-
-
Beijing, Kina
- Gan & Lee Pharmaceuticals
-
Kontakt:
- Kunlin Li
- Telefonnummer: 010-80595000
- E-post: Kunlin.li@ganlee.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Signed the informed consent form (ICF) prior to study procedures, fully understood the study content, procedures and potential adverse reactions, and agreed to comply with the study protocol.
- Aged 18 to 45 years (inclusive, based on the date of ICF ); male or female.
Exclusion Criteria:
- History of atopic diathesis, or allergic diseases such as bronchial asthma, urticaria, and eczema; known hypersensitivity or intolerance to the investigational product, its analogous products, or excipients.
- Positive screening test for any of the following: hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), human immunodeficiency virus antibody (HIV-Ab), treponema pallidum antibody (TP-Ab).
- Participation in another clinical trial of investigational medicinal products or medical devices with receipt of study treatment within 3 months prior to screening.
- Participants who donated blood or blood product (>400 mL) or significant blood loss (>200 mL) within 6 months prior to screening, or plan to donate blood or blood products during the study.
- History of substance abuse or illicit drug use within 1 year prior to screening, or positive drug abuse screening test.
- Average daily tobacco consumption of more than 5 cigarettes within 3 months prior to screening, or inability to abstain from tobacco-containing products (cigarettes, chewing tobacco, etc.) during the study.
- History of vasovagal syncope related to needle or blood exposure, or difficult venous access for blood collection.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Crossover tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: GZR33 Injection-Abdomen
Participants will receive a single-dose administration of GZR33 Injection(s.c. inthe abdomen , the upper arm and the thigh) on different occasions. |
Administered subcutaneously (s.c.) |
|
Experimentell: GZR33 Injection-Upper Arm
Participants will receive a single-dose administration of GZR33 Injection(s.c. inthe abdomen , the upper arm and the thigh) on different occasions. |
Administered subcutaneously (s.c.) |
|
Experimentell: GZR33 Injection- Thigh
Participants will receive a single-dose administration of GZR33 Injection(s.c. inthe abdomen , the upper arm and the thigh) on different occasions. |
Administered subcutaneously (s.c.) |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
AUC₀-₁₂₀ h
Tidsram: 0 hours to 120 hours after study drug administration
|
0 hours to 120 hours after study drug administration
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
AUC₀-∞
Tidsram: 0 hours to 120 hours after study drug administration
|
0 hours to 120 hours after study drug administration
|
|
Cmax
Tidsram: 0 hours to 120 hours after study drug administration
|
0 hours to 120 hours after study drug administration
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- GZR33-T2D-101
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .